Results 21 to 30 of about 14,264 (186)

Flexibility in insulin prescription

Indian Journal of Endocrinology and Metabolism, 2016
This communication explores the concept of flexibility, a propos insulin preparations and insulin regimes used in the management of type 2 diabetes.
Sanjay Kalra, Yashdeep Gupta, Ambika Gopalakrishnan Unnikrishnan   +2 more
doaj   +1 more source

Effects of glargine on hyperglycemia in patients with diabetes mellitus type II undergoing off-pump coronary artery bypass graft: A randomized, controlled, double-blind clinical trial [PDF]

Journal of Cardiovascular and Thoracic Research, 2023
Introduction: In this trial, effects of glargine on hyperglycemia in patients with diabetes mellitus type II who were undergoing off-pump coronary artery bypass graft (CAGB), were examined.
Shima Sheybani, Mahdi Kahrom, Raheleh Ganjali, Seyedeh Mahsa Kalati, Nahid Zirak, Vahideh Ghorani   +5 more
doaj   +1 more source

An overview of insulin glargine

Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do ...
Home PD; Ashwell SG
core   +5 more sources

Improved Cardiovascular and Cardiometabolic Risk in Patients With Type 1 Diabetes and Autoimmune Polyglandular Syndrome Switched From Glargine to Degludec Due to Hypoglycaemic Variability

Frontiers in Endocrinology, 2018
Background: Cardiovascular disease is a frequent complication of type 1 diabetes (T1D). We evaluated the effectiveness of switching from glargine to degludec in reducing the cardiovascular risk factors, the Framingham risk score (FRS) and visceral ...
Valentina Guarnotta, Giulia Di Bella, Giuseppe Pillitteri, Alessandro Ciresi, Carla Giordano   +4 more
doaj   +1 more source

Place of insulin therapy in current approaches to the treatment of type 2 diabetes

Медицинский совет, 2016
Type 2 diabetes mellitus (T2DM) is a high risk factor for the development of macrovascular complications. Several large studies have demonstrated the fundamental role of early extensive blood glucose control in the prevention of these complications.
O. Y. Gurova, V. V. Fadeev
doaj   +1 more source

Insulin/carbohydrates ratio during the first 6‐month therapy with insulin degludec in a paediatric population with type 1 diabetes previously treated with insulin glargine. An observational longitudinal study

Endocrinology, Diabetes & Metabolism, 2020
Background No data exist about the changes induced by the transition from first‐generation long‐acting insulins to second‐generation long‐acting analogues in the paediatric population.
Stefano Tumini, Olimpia Iacono, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +12 more
doaj   +1 more source

The effect of combination therapy of insulin glargine, metformin, and sitagliptin on insulin secretion, insulin resistance, and metabolic parameters in obese subjects with type 2 diabetes [PDF]

Srpski Arhiv za Celokupno Lekarstvo, 2016
Introduction. A combination of drugs is required for treatment of obese subjects with diabetes, due to multiple pathogenic mechanisms implicated in the development of both diabetes and obesity. Objective.
Beljić-Živković Teodora, Marjanović-Petković Milica, Vuksanović Miljanka, Soldatović Ivan, Kanlić Dobrila, Topalov Drina   +5 more
doaj   +1 more source

Insulin Glargine and Risk of Cancer: A Meta-Analysis

The International Journal of Biological Markers, 2012
Aims Recently, more and more attention has been drawn on the long-term effects of insulin glargine. Here we strived to estimate the association of cancer occurrence with the use of insulin glargine.
Xinli Du, Rihua Zhang, Yi Xue, Dong Li, Jinmei Cai, Suming Zhou, Zhengkai Huang, Rongbin Yu, Yun Liu Phn   +8 more
doaj   +1 more source

Insulin Toujeo® — a Novel Basal Long-Acting Insulin Formulation. Part 2. Clinical Efficacy and Safety

Mìžnarodnij Endokrinologìčnij Žurnal, 2015
This review, consisting of two parts, considers a new formulation of insulin glargine (rDNA origin) in the form of injections 300 U/ml (Gla-300, Toujeo®).
V.V. Poltorak, N.А. Kravchun, M.Yu. Gorshunska   +2 more
doaj   +1 more source

Effectiveness and safety of flexible therapeutic schemes including first- and secondgeneration basal insulins during a pediatric summer diabetes camp

Pediatric Reports, 2020
Outcomes of insulin analogues in pediatric diabetes camps are poorly investigated; no data is available about insulin degludec (IDeg).Our aim was to assess impact of insulin therapy adopted by the participants to a 4-day diabetes camp held in 2017 ...
Stefano Tumini, Laura Comegna, Elisabetta Fioretti, Paola Guidone, Gabriella Levantini, Daniele Panichi, Milena Catenaro, Ilaria Rossi, Flavia Amaro, Giusi Graziano, Maria Chiara Rossi, Paola Cipriano   +11 more
doaj   +1 more source